Algert Global LLC Sells 58,194 Shares of Kura Oncology, Inc. $KURA

Algert Global LLC lowered its position in Kura Oncology, Inc. (NASDAQ:KURA) by 5.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,011,945 shares of the company’s stock after selling 58,194 shares during the quarter. Algert Global LLC owned 1.16% of Kura Oncology worth $8,956,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. Ameriprise Financial Inc. increased its position in Kura Oncology by 2,428.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 327,564 shares of the company’s stock valued at $2,899,000 after acquiring an additional 314,609 shares during the period. Creative Planning lifted its holdings in shares of Kura Oncology by 29.9% during the third quarter. Creative Planning now owns 177,055 shares of the company’s stock worth $1,567,000 after purchasing an additional 40,796 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Kura Oncology by 222.3% during the third quarter. Lazard Asset Management LLC now owns 10,423 shares of the company’s stock worth $92,000 after purchasing an additional 7,189 shares during the period. California State Teachers Retirement System grew its stake in shares of Kura Oncology by 46.6% in the third quarter. California State Teachers Retirement System now owns 65,867 shares of the company’s stock worth $583,000 after purchasing an additional 20,944 shares during the last quarter. Finally, ADAR1 Capital Management LLC grew its stake in shares of Kura Oncology by 60.3% in the third quarter. ADAR1 Capital Management LLC now owns 55,000 shares of the company’s stock worth $487,000 after purchasing an additional 20,700 shares during the last quarter.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 8,180 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total value of $69,202.80. Following the completion of the sale, the insider directly owned 267,274 shares in the company, valued at approximately $2,261,138.04. The trade was a 2.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Thomas James Doyle sold 7,142 shares of Kura Oncology stock in a transaction on Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $60,421.32. Following the completion of the sale, the senior vice president directly owned 145,167 shares of the company’s stock, valued at approximately $1,228,112.82. This trade represents a 4.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 59,794 shares of company stock valued at $537,176 in the last 90 days. Company insiders own 6.40% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research report on Tuesday, January 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Wedbush lowered their price objective on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, March 6th. Finally, Leerink Partners set a $20.00 price objective on Kura Oncology and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.57.

Kura Oncology Price Performance

KURA stock opened at $8.73 on Tuesday. The firm has a market cap of $771.12 million, a price-to-earnings ratio of -2.75 and a beta of 0.22. The company has a quick ratio of 6.05, a current ratio of 6.06 and a debt-to-equity ratio of 0.06. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $12.49. The company’s fifty day simple moving average is $8.61 and its 200 day simple moving average is $9.48.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 102.59%. The firm had revenue of $17.34 million for the quarter, compared to the consensus estimate of $34.71 million. On average, analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.